Strides Pharma Science Limited announced on 22 May 2025 the outcome of its Board Meeting:

• The Board of Directors approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended 31 March 2025.
• A final dividend of ₹4/- per equity share of ₹10/- each (at the rate of 40%) was recommended for the financial year ended 31 March 2025. This dividend will be paid within 30 days from the date of Shareholders’ approval at the ensuing Annual General Meeting (AGM).
• M/s. B S R & Co. LLP, the Statutory Auditors, have issued an unmodified opinion on both the standalone and consolidated audited financial results for the financial year ended 31 March 2025.
• The auditors' report includes an "Emphasis of Matter" note, highlighting the restatement of audited consolidated and standalone financial results for the quarter and year ended 31 March 2024. This restatement is a consequence of the Scheme of Arrangement for the demerger of the CDMO and Soft Gelatin Business, approved by the National Company Law Tribunal (NCLT) on 14 November 2024, with a retrospective appointed date of 1 April 2024. This accounting treatment overrides a relevant requirement of Appendix A to Ind AS 10.
• Additionally, the standalone financial results for the year ended 31 March 2025 include the merger of Strides Alathur Private Limited with the Holding Company, effective 1 April 2023, as per NCLT order dated 13 August 2024. Corresponding figures for the year ended 31 March 2024 have been restated.